Surface Oncology, Inc. (SURF)
(Delayed Data from NSDQ)
$4.87 USD
+0.02 (0.41%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.84 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.87 USD
+0.02 (0.41%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.84 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Walgreens (WBA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Walgreens' (WBA) strategic executions on the United States and the international front is likely to have contributed to the Q2 2023 top line.
Lantheus Holdings (LNTH) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 42.71% and 7.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Envista (NVST) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Envista (NVST) delivered earnings and revenue surprises of 6.12% and 0.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
TG Therapeutics (TGTX) Soars 8.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Why Surface Oncology (SURF) Might Surprise This Earnings Season
by Zacks Equity Research
Surface Oncology (SURF) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Surface Oncology, Inc. (SURF) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Surface Oncology, Inc. (SURF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Perrigo (PRGO) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Perrigo (PRGO) delivered earnings and revenue surprises of 7.14% and 0.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Medtronic (MDT) Q3 Earnings Top Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of 0.74% and 1.60%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for September 13th
by Zacks Equity Research
AFMD, DZSI, GMBL, NTRB, and SURF have been added to the Zacks Rank #5 (Strong Sell) List on September 13, 2021.
Implied Volatility Surging for Surface Oncology (SURF) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Surface Oncology (SURF) stock based on the movements in the options market lately.
Surface Oncology, Inc. (SURF) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Surface Oncology, Inc. (SURF) delivered earnings and revenue surprises of 345.71% and 3.02%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Surface Oncology (SURF) is Oversold: Can It Recover?
by Zacks Equity Research
Surface Oncology (SURF) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Should You Buy Surface Oncology (SURF) Ahead of Earnings?
by Zacks Equity Research
Surface Oncology (SURF) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Surface Oncology, Inc. (SURF) to Report Q4 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Surface Oncology, Inc. (SURF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cooper Companies (COO) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal first-quarter results are likely to reflect strength at MiSight 1-day contact lens.
What's in Store for Patterson Companies' (PDCO) Q3 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal third-quarter results are likely to reflect improvement at Dental segment.
Veeva Systems (VEEV) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal fourth-quarter results are likely to reflect solid show by its segments and robust product portfolio.
ResMed (RMD) Q2 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
ResMed (RMD) reported second-quarter fiscal 2021 revenues of $800 million, up 9% from a year ago.
Allscripts (MDRX) Extends Tie-Up With US Orthopedic Alliance
by Zacks Equity Research
Allscripts (MDRX) extends strategic partnership with US Orthopedic Alliance to form a more scalable orhopedic services technology platform.
Are Options Traders Betting on a Big Move in Surface Oncology (SURF) Stock?
by Zacks Equity Research
Investors need to pay close attention to Surface Oncology (SURF) stock based on the movements in the options market lately.
Earnings Estimates Moving Higher for Surface Oncology, Inc. (SURF): Time to Buy?
by Zacks Equity Research
Surface Oncology, Inc. (SURF) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks.com featured highlights include: Matson, Surface Oncology, Green Brick Partners, Merchants Bancorp and Herc Holdings
by Zacks Equity Research
Zacks.com featured highlights include: Matson, Surface Oncology, Green Brick Partners, Merchants Bancorp and Herc Holdings
5 Stocks With Recent Price Strength Under Severe Volatility
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Zacks.com featured highlights include: Daqo, Surface Oncology, Covenant, Herc and Castle Biosciences
by Zacks Equity Research
Zacks.com featured highlights include: Daqo, Surface Oncology, Covenant, Herc and Castle Biosciences
5 Stocks With Recent Price Strength to Maximize Your Gains
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.